Companies: 10,795·Total market cap: $144.5T
Global Medical REIT Inc.

Global Medical REIT Inc.

GMRENYSEReal Estate
$35.74
$-0.45(-1.24%)
Market Cap$478125610
P/E Ratio
52W High$45.75
52W Low$29.05
Overview

Global Medical REIT Inc. (GMRE) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

gmre · stock forecast · 22 analysts (3M) · FMP · updated Mar 26, 2026

Analyst Rating & Consensus

Based on 22 Wall Street analysts in the past 3 months

SellBuy

Buy

22 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
13
Hold
9
Sell
0
Strong Sell
0
Total: 22 · Buy rate: 59.1%

12-Month Price Target

High

$40.00

Consensus

$20.92

-37.1% upside

Low

$11.00

Median: $11.75 · Last Close: $33.24

The Global Medical REIT Inc. (GMRE) analyst consensus is Buy, based on ratings from 22 Wall Street analysts over the past 3 months. The average 12-month GMRE price target is $20.92, representing -37.1% upside from the current price of $33.24.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $21 (-37.1%)

Consensus Target

$20.92

-37.1% upside

High Target

$40

20.3%

Low Target

$11

-66.9%

Current Price

$33.24

as of today

Based on analyst price targets, the GMRE stock price prediction for the next 12 months ranges from $11 to $40. The consensus GMRE price forecast of $20.92 implies -37.1% upside from the current price of $33.24.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$32.532.13%

1-day model range: $32.4–$32.66. Peak: $32.66 (-2.13%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$33-1.0%
2028$33-1.6%
2029$33-1.9%
2030$33-2.1%
2031-2.2%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

21%8%71%
3Buy
1Neutral
10Sell
RSI (14)47.8Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · GMRE · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$32.88BUY
MA 10$33.06BUY
MA 20$33.93SELL
MA 50$35.06SELL
MA 100$34.43SELL
MA 200$34.33SELL
Current $GMRE · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$33.07BUY
EMA 10$33.27SELL
EMA 20$33.82SELL
EMA 50$34.49SELL
EMA 100$34.56SELL
EMA 200$35.17SELL
Current $GMRE · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Baird2025-11-11
Maintains
NeutralNeutral
JMP Securities2025-10-13
Upgrade ↑
Market PerformMarket Outperform
Baird2025-05-08
Maintains
NeutralNeutral
Citizens Capital Markets2025-03-12
Maintains
Market PerformMarket Perform
B. Riley Securities2024-05-13
Maintains
BuyBuy
B. Riley Securities2023-05-08
Maintains
BuyBuy
B. Riley Securities2023-03-06
Maintains
BuyBuy
Baird2022-10-10
Downgrade ↓
OutperformNeutral
BMO Capital2022-10-06
Downgrade ↓
OutperformMarket Perform
Keybanc2022-01-13
Downgrade ↓
OverweightSector Weight

Wall Street analysts have recently issued updated ratings on Global Medical REIT Inc. (GMRE) stock. Of the recent 47 rating actions, 7 were upgrades and 11 were downgrades. 22 analysts currently cover GMRE.

Analyst Recommendation Trends

Buy ratings101
Hold ratings01↑ +1
Sell ratings00

GMRE analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$147M

↓ 7.0% YoY

Revenue Next Year

$151M

↑ 3.0% YoY

EPS This Year

$-0.26

EPS Next Year

$0.06

↓ 123.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast GMRE EPS of $-0.26 for the current fiscal year, based on estimates from 1 analysts. The GMRE revenue forecast is $147M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The GMRE stock forecast is supported by two independent data sources: analyst consensus ratings from 22 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GMRE price target is $20.92 (-37.1% upside), with an analyst consensus of Buy.

The GMRE short-term stock prediction for tomorrow is $32.53 (-2.13%). The GMRE stock price prediction for 2027 estimates an average of $33. The GMRE stock prediction for 2030 projects a range of $31–$34.

Global Medical REIT Inc. trades on NYSE under the ticker GMRE. The GMRE stock outlook for 2027 is broadly positive, supported by a Buy consensus among 59% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

GMRE forecast · 8 questions

According to 22 Wall Street analysts, the average 12-month GMRE price target is $20.92, with a high forecast of $40.00 and a low of $11.00. The median price target is shown in the chart above when available. This implies -37.1% potential upside from the current price of $33.24.

GMRE price targetWhat is GMRE price targetGMRE analyst price targetGMRE 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.